Valbenazine for Huntington's Disease

"This study requires that all participants are between 18-75 years old."

"Valbenazine's safety is estimated to be a 3. This judgement comes from the fact that this medication is in Phase 3 trials, meaning that there is both evidence of its efficacy and multiple rounds of data supporting its safety."

"That is correct. The information available on clinicaltrials.gov attests that this trial is still actively looking for subjects. This particular study was first posted on September 18th, 2020 and was most recently edited on October 31st, 2022. In total, they are looking to have 150 participants at 33 locations across the country."

"To be eligible for this study, participants must have Huntington's disease, be aged 18-75, and meet either requirement #1 or #2. Additionally, candidates must be able to walk unassisted or with the help of a mobility device. Those who have participated in Study NBI-98854-HD3005 are ineligible."

"The trial is currently seeking patients, according to the information on clinicaltrials.gov. This study was first posted on September 18th 2020 and was most recently updated on October 31st 2022."

"Valbenazine has been under investigation since 2020. The first study was a Phase 1 clinical trial sponsored by Neurocrine Biosciences. After the initial success in 2020, which involved 150 participants, Valbenazine received approval for Phase 3 trials. Currently, there are 3 live trials taking place across 52 cities in 2 countries."

"Valbenazine was first studied in 2020 by Neurocrine, and since then there have been 19 completed clinical trials. As of now, 3 more studies are underway with active recruitment. These trials are primarily based out of Toronto, Canada."

"33 clinical trial sites are currently operational. These locations include major cities such as Toronto, Omaha and Chicago. There may be a location near you, which would reduce travel time if you decided to participate in this study."